CTRI/2021/07/034692已完成1 期
A phase I, prospective, open label, multiple dose study of ZYIL1 administered via oral route to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adult subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- To evaluate safety and tolerability of ZYIL1 administered to healthy subjects.
研究概览
简要总结
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway. ZYIL1 is expected to show benefit in patients demonstrating cytokine, like IL1β flare, including those exhibiting cytokine storm related to COVID-19 and other inflammatory diseases.
This Study aims to determine the pharmacokinetics , pharmacodynamics, safety and tolerability of ZYIL1 when administered in multiple doses of 14 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 55.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Healthy male or non-lactating non-pregnant female between 18 and 55 years of age at the time of signing the informed consent form (ICF).
- •(Both inclusive).
- •2.Body mass index of 18.5 to 30.0 kg/m2 (Both inclusive) with a body weight of 50 to 100 kg (Both inclusive).
- •3.Normal QTc interval at screening and Check In [QTcF ≤450 ms] 4.Male subjects must agree to use adequate contraception methods during the study and be willing and able to continue contraception for 90 days after administration of study treatment.
- •5.Capable of giving written informed consent, which includes compliance with the study procedures, restrictions, and requirements listed in the protocol.
- •6.Subjects who, in the opinion of the Investigator, are healthy as determined by their pre study medical history, clinical examination, 12-lead ECG and clinical laboratory tests within the institutional normal range or judged as not clinically significant by the Investigator, including the following parameters: hematology, serum biochemistry, urinalysis, and serology.
- •7.Female subjects with history of sterility or at least 1 year menopause or use of long acting non hormonal contraceptive measures (e.g., intrauterine device) and be willing and able to continue contraception for 90 days after administration of study treatment.
排除标准
- •1.History or presence of alcoholism or drug abuse within the past 1 year.
- •2.Presence or history of any of the following disorders/disease within the past 3 months, that might have impact on the clinical trial as per the investigator discretion: cardiovascular, cerebrovascular, dermatological, gastrointestinal, gynecological, hematological, hepatic, malignancy, metabolic, musculoskeletal, neurological, urological, psychiatric, renal, respiratory, venereal, any other major disorders 3.History of clinically significant hypersensitivity, intolerance, or allergies, as determined by the Investigator.
- •4.History of COVID-19 infection within 14 days or contact with a confirmed active COVID-19 positive patient within 14 days; or positive COVID-19 test within 5 days of Check-in.
- •5.History or presence of smoking or consumption of tobacco/nicotine products within the past 1 year.
- •6.Difficulty with donating blood.
- •7.Systolic blood pressure more than 140 mmHg or less than 100 mmHg or diastolic blood pressure more than 90 mmHg or less than 60 mmHg. 8.Pulse rate less than 55/minute or more than 100/minute.
- •9.Any clinically significant laboratory or ECG findings during screening 10.Surgery within last 3 months or planned major surgery within next 3 months from the date of screening (other than minor cosmetic surgery and minor dental surgery).
- •11.Subjects who have recent illness (eg, fever) within 14 days of check-in 12.Volunteers who have participated in any drug research study within past 3 months.
- •13.Volunteers who have donated one unit (350 ml) of blood in the past 3 months.
- •14.Has used prescription drugs and other substances (eg, dietary or herbal supplements such as St John’s Wort) known to be either significant enzyme inducers or enzyme inhibitors within 4 weeks of Day 1, or use of grapefruit or similar substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or fruit juices) within 7 days of Day
- •15.Use of any over-the-counter (OTC), any prescription medications or alternative tradition of medicine (herbal medicines, homoeopathy, Siddha, Unani, etc.) within the 15 days or 5 half-lives (whichever is longer), prior to receiving study drug that might have impact on the clinical trial as per the investigator discretion.
- •16.A positive urine drugs of abuse test or positive alcohol test at check-in.
- •17.History of, or positive screening test for, hepatitis C infection (defined as positive for hepatitis C virus antibody), hepatitis B infection (defined as positive for hepatitis B surface antigen), or human immunodeficiency virus I or II.
- •18.Any disorder that, in the Investigator’s opinion, may interfere with study compliance, such as significant mental, nervous disorder or other illness.
- •In making this assessment, the Investigator must refer to the study information provided including the Investigator’s Brochure.
- •19.Inability to be venipuncture or tolerate venous puncture.
- •20.Any condition or abnormal baseline findings that in the Investigator’s judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study.
- •21.Other unspecified reasons that, in the opinion of the Investigator or the Sponsor, make the subject unsuitable for the study.
- •22.Female subjects who are pregnant, currently breastfeeding, or attempting to conceive.
结局指标
主要结局
To evaluate safety and tolerability of ZYIL1 administered to healthy subjects.
时间窗: Screening and Day 16
次要结局
- •To characterize the pharmacokinetics of ZYIL1 when administered as a multiple oral dose to healthy subjects.(Day 1, Day 2, Day 3, Day 5, Day 7, Day 10, Day 13, Day 14, Day 15 and Day 16)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy VolunteersHealthyNCT04972188Zydus Lifesciences Limited18
进行中（未招募）
1 期
A Study Of Phase I dose escalation trial of ZYIL1 Via Oral Route To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Healthy Adult Human SubjectsHealthyCTRI/2020/12/030045Cadila Healthcare Ltd42
已完成
1 期
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy VolunteersHealthyNCT04731324Zydus Lifesciences Limited30
已完成
2 期
A study to evaluate Safety,Efficacy,Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in patients with Amyotrophic Lateral SclerosisOther inherited spinal muscular atrophy,CTRI/2023/10/058660Zydus Lifesciences Limited24
已完成
2 期
Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT05981040Zydus Lifesciences Limited24